200 related articles for article (PubMed ID: 24534655)
1. Correlates of self-reported quality of life in adults and children with morphea.
Das S; Bernstein I; Jacobe H
J Am Acad Dermatol; 2014 May; 70(5):904-10. PubMed ID: 24534655
[TBL] [Abstract][Full Text] [Related]
2. An Evaluation of the Performance of Current Morphea Subtype Classifications.
Prasad S; Zhu JL; Schollaert-Fitch K; Torok KS; Jacobe HT
JAMA Dermatol; 2021 Apr; 157(4):1-8. PubMed ID: 33595618
[TBL] [Abstract][Full Text] [Related]
3. The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IV.
Grabell D; Hsieh C; Andrew R; Martires K; Kim A; Vasquez R; Jacobe H
J Am Acad Dermatol; 2014 Sep; 71(3):493-8. PubMed ID: 24880663
[TBL] [Abstract][Full Text] [Related]
4. Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V.
Walker D; Susa JS; Currimbhoy S; Jacobe H
J Am Acad Dermatol; 2017 Jun; 76(6):1124-1130. PubMed ID: 28285783
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.
Kim A; Marinkovich N; Vasquez R; Jacobe HT
J Rheumatol; 2014 Jan; 41(1):106-12. PubMed ID: 24293577
[TBL] [Abstract][Full Text] [Related]
6. Morphea in adults and children cohort II: patients with morphea experience delay in diagnosis and large variation in treatment.
Johnson W; Jacobe H
J Am Acad Dermatol; 2012 Nov; 67(5):881-9. PubMed ID: 22382198
[TBL] [Abstract][Full Text] [Related]
7. Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort.
Kunzler E; Florez-Pollack S; Teske N; O'Brien J; Prasad S; Jacobe H
J Am Acad Dermatol; 2019 Jun; 80(6):1664-1670.e1. PubMed ID: 31005342
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort.
Condie D; Grabell D; Jacobe H
Arthritis Rheumatol; 2014 Dec; 66(12):3496-504. PubMed ID: 25156342
[TBL] [Abstract][Full Text] [Related]
9. Interventions for morphea.
Albuquerque JV; Andriolo BN; Vasconcellos MR; Civile VT; Lyddiatt A; Trevisani VF
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD005027. PubMed ID: 31309547
[TBL] [Abstract][Full Text] [Related]
10. Association between quality of life and clinical characteristics in patients with morphea.
Bali G; Kárpáti S; Sárdy M; Brodszky V; Hidvégi B; Rencz F
Qual Life Res; 2018 Oct; 27(10):2525-2532. PubMed ID: 29922914
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature.
Szczęch J; Samotij D; Jaworecka K; Tobiasz A; Reich A
Biomed Res Int; 2020; 2020():9186274. PubMed ID: 32258158
[TBL] [Abstract][Full Text] [Related]
12. Changes in Disease Activity and Damage Over Time in Patients With Morphea.
O'Brien JC; Nymeyer H; Green A; Jacobe HT
JAMA Dermatol; 2020 May; 156(5):513-520. PubMed ID: 32236501
[TBL] [Abstract][Full Text] [Related]
13. Morphea patients with mucocutaneous involvement: A cross-sectional study from the Morphea in Adults and Children (MAC) cohort.
Prasad S; Black SM; Zhu JL; Sharma S; Jacobe H
J Am Acad Dermatol; 2021 Jul; 85(1):114-120. PubMed ID: 33249064
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic and therapeutic problems of scleroderma].
Pogorzelska-Antkowiak A; Antkowiak R
Wiad Lek; 2006; 59(5-6):392-5. PubMed ID: 17017489
[TBL] [Abstract][Full Text] [Related]
15. Skin mapping for the classification of generalized morphea.
Teske N; Welser J; Jacobe H
J Am Acad Dermatol; 2018 Feb; 78(2):351-357. PubMed ID: 29332706
[TBL] [Abstract][Full Text] [Related]
16. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea.
Kencka D; Blaszczyk M; Jabłońska S
Dermatology; 1995; 190(3):203-6. PubMed ID: 7599381
[TBL] [Abstract][Full Text] [Related]
17. Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea.
Dharamsi JW; Victor S; Aguwa N; Ahn C; Arnett F; Mayes MD; Jacobe H
JAMA Dermatol; 2013 Oct; 149(10):1159-65. PubMed ID: 23925398
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of Health-Related Quality of Life Impact in Juvenile Localized Scleroderma.
Sanchez-Espino LF; Luca N; Pope E; Laxer RM; Knight AM; Sibbald C
Arthritis Care Res (Hoboken); 2024 Mar; 76(3):340-349. PubMed ID: 37750181
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea.
García-Romero MT; Tollefson M; Pope E; Brandling-Bennett HA; Paller AS; Keimig E; Arkin L; Wanat KA; Humphrey SR; Werth VP; Oza V; Jacobe H; Fett N; Cordoro KM; Medina-Vera I; Chiu YE
JAMA Dermatol; 2023 Mar; 159(3):299-307. PubMed ID: 36753150
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma.
Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Am Acad Dermatol; 1994 Oct; 31(4):567-71. PubMed ID: 8089281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]